AdaptHealth Corp. (AHCO)
| Market Cap | 1.43B +20.5% |
| Revenue (ttm) | 3.29B +1.2% |
| Net Income | -79.63M |
| EPS | -0.59 |
| Shares Out | 133.12M |
| PE Ratio | n/a |
| Forward PE | 11.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,342,146 |
| Open | 10.70 |
| Previous Close | 10.66 |
| Day's Range | 10.66 - 11.03 |
| 52-Week Range | 8.06 - 13.43 |
| Beta | 1.57 |
| Analysts | Buy |
| Price Target | 14.00 (+30.6%) |
| Earnings Date | May 5, 2026 |
About AHCO
AdaptHealth Corp., together with its subsidiaries, distributes home medical equipment (HME), medical supplies, and home and related services in the United States. It operates through Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home segments. The company offers sleep therapy equipment, supplies, and related services, such as continuous positive airway pressure and BiLevel services to individuals suffering from obstructive sleep apnea; oxygen and home mechanical ventilation equipment and supplies and related chronic therapy... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for AHCO stock is "Buy." The 12-month stock price target is $14.0, which is an increase of 30.60% from the latest price.
News
AdaptHealth Transcript: Bank of America Global Healthcare Conference 2026
All business segments grew organically in Q1, with a major new capitated contract driving revenue and expected to reach a 20% margin by 2026. Investments in infrastructure and technology are improving efficiency, while regulatory changes and disciplined M&A support future growth.
AdaptHealth price target raised to $15 from $13 at RBC Capital
RBC Capital raised the firm’s price target on AdaptHealth (AHCO) to $15 from $13 and keeps an Outperform rating on the shares. The firm is adjusting its model after the…
AdaptHealth price target raised to $18 from $17 at Baird
Baird analyst Eric Coldwell raised the firm’s price target on AdaptHealth (AHCO) to $18 from $17 and keeps an Outperform rating on the shares. The firm updated its model following…
AdaptHealth price target raised to $16 from $14 at Canaccord
Canaccord raised the firm’s price target on AdaptHealth (AHCO) to $16 from $14 and keeps a Buy rating on the shares. The firm updated its model following Q1 results where…
AdaptHealth price target lowered to $14 from $15 at UBS
UBS lowered the firm’s price target on AdaptHealth (AHCO) to $14 from $15 and keeps a Buy rating on the shares.
AdaptHealth Corp. to Participate in Upcoming Investor Conferences
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medi...
AdaptHealth Earnings Call Transcript: Q1 2026
Revenue and organic growth exceeded guidance, driven by a major capitated contract and strong segment performance. Labor and startup costs impacted Q1 margins, but normalization and full contract ramp are expected to boost profitability and cash flow in the coming quarters.
AdaptHealth Earnings release: Q1 2026
AdaptHealth released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
AdaptHealth Slides: Q1 2026
AdaptHealth has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
AdaptHealth Quarterly report: Q1 2026
AdaptHealth has published its Q1 2026 quarterly earnings report on May 5, 2026.
AdaptHealth reports Q1 EPS (12c), consensus 1c
Reports Q1 revenue $819.799M, consensus $796.63M. “The opening months of 2026 have set the stage for what will be a defining year for AdaptHealth (AHCO),” said Suzanne Foster, Chief Executive…
AdaptHealth sees FY26 net revenue $3.45B-$3.52B, consensus $3.47B
For fiscal year 2026, the Company is raising net revenue guidance by $10 million and maintaining Adjusted EBITDA and free cash flow guidance, as follows: Net revenue of $3.45 billion…
AdaptHealth Corp. Announces First Quarter 2026 Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medi...
AdaptHealth Proxy statement: Proxy filing
AdaptHealth filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
AdaptHealth price target raised to $11 from $9.50 at Jefferies
Jefferies analyst Brian Tanquilut raised the firm’s price target on AdaptHealth (AHCO) to $11 from $9.50 and keeps a Hold rating on the shares. The relative underperformance of healthcare services…
AdaptHealth Corp. Announces First Quarter 2026 Earnings Release Date and Conference Call
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medi...
AdaptHealth price target raised to $14 from $13 at Truist
Truist raised the firm’s price target on AdaptHealth (AHCO) to $14 from $13 and keeps a Buy rating on the shares as part of a broader research note previewing Q1…
AdaptHealth announces refinancing of senior secured credit facility
AdaptHealth (AHCO) announced that it has closed a $1.1B senior secured credit facility, consisting of a $325M Term Loan A, a $325M Delayed Draw Term Loan, and a $450M revolving…
AdaptHealth Corp. Announces Refinancing of Senior Secured Credit Facility Resulting in Extended Maturity, Reduced Cost of Debt, and Enhanced Financial Flexibility
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medi...
AdaptHealth rallies after CEO buys $4.4M of shares
Shares of AdaptHealth (AHCO) are moving higher after the company’s CEO Richard Cashin last night disclosed the purchase of 447,827 shares between March 19 and March 20 at an average…
AdaptHealth Transcript: Leerink Global Healthcare Conference 2026
Major operational streamlining and technology investments have driven record setup times and census growth across core segments. Exclusive capitated contracts with major payers like Kaiser and Humana are fueling expansion, while divestitures and M&A refine the portfolio. Regulatory changes and payer mix shifts continue to shape strategy.
AdaptHealth Transcript: J.P. Morgan 2026 Global Leveraged Finance Conference
The company is expanding its market share in sleep and respiratory care, leveraging technology and operational improvements to drive high adherence and patient satisfaction. Major contracts with Humana and Kaiser are fueling geographic growth, especially on the West Coast, while regulatory changes and industry consolidation present further opportunities.
HALPER SADEH LLC ENCOURAGES ADAPTHEALTH CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is invest...
AdaptHealth price target lowered to $9.50 from $10.50 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on AdaptHealth (AHCO) to $9.50 from $10.50 and keeps a Hold rating on the shares.
AdaptHealth price target lowered to $14 from $15 at Canaccord
Canaccord lowered the firm’s price target on AdaptHealth (AHCO) to $14 from $15 and keeps a Buy rating on the shares. The firm said Adapt closed the year with much…